<DOC>
	<DOCNO>NCT00005963</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel carboplatin treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Carboplatin Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine anti-tumor activity docetaxel carboplatin woman metastatic adenocarcinoma breast . II . Determine objective response rate , time progression , survival patient treat regimen . III . Determine toxic effect regimen patient . IV . Assess common functional polymorphism gene involve chemotherapeutic response improve prediction clinical outcome provide insight potential genotype-specific drug dosage . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour carboplatin IV 30 minute day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients achieve stable disease ( SD ) , partial response ( PR ) , complete response ( CR ) may receive 4 additional course past SD , PR , CR . Patients follow every 6 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma breast Measurable disease At least 20 mm least 1 dimension Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 2.5 time ULN Alkaline phosphatase great ULN OR SGOT/SGPT great ULN Alkaline phosphatase great 4 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure No unstable angina No clinically significant pericardial effusion arrhythmia Other : No invasive malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No active unresolved infection No prior hypersensitivity reaction docetaxel No grade 2 great sensory motor neuropathy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent prophylactic filgrastim ( GCSF ) first course study therapy Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy allow More 1 year since prior paclitaxel , docetaxel , cisplatin , carboplatin No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy breast , chest wall , axilla No prior radiotherapy great 30 % bone marrow No concurrent radiotherapy Surgery : At least 4 week since prior major surgery recover Other : More 7 day since prior IV antibiotic No concurrent experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>